Share the Video:

Preliminary results from a Pilot study of the efficacy and safety of ibogaine in the treatment of methadone detoxification

Jose Carlos Bouso

Ibogaine is the most promising psychedelic with regards to the treatment of substance use disorders. Despite its widespread use in private clinics and underground settings worldwide, there is a scarcity of randomized controlled trials evaluating its safety and efficacy. This study, which is the first Phase-II study of ibogaine for the treatment of methadone dependence, aims to validate a safe clinical protocol for detoxification purposes. Publicly funded and conducted in collaboration with Hospital Universitari Sant Joan de Reus, promoted by ICEERS, the study evaluates the safety and efficacy of low doses of ibogaine on a weekly basis for six weeks. The results of this study will provide valuable information for further research and the advancement of safe clinical use of ibogaine.

Become a MAPS Member with a monthly donation

As a Member, you’re not just making a donation — you’re joining a community that is at the forefront of advancing research, changing policy, and evolving education around psychedelics. Join us in shaping a future where these life-changing tools are available to those who need them most.

The Canadian Psychedelic Survey; Results of a Large Cross-Sectional Survey of Canadian Adults Who Use Psychedelics

Canadian Psychedelic Survey collected real-world evidence from 2393 Canadian adults on psychedelic use, revealing patterns, effects, and reasons for use. Results may influence policy and treatment approaches.

Philippe Lucas

PS2023 Harm Reduction Health Conditions Ketamine Psychedelic Science Research and Science Substance Use Disorder

The Mirror Molecule: How can ketamine and other substances be both addictive and anti-addictive?

Ketamine and psilocybin show promise for health conditions but come with risks, including addiction. This talk challenges the view of drugs as neutral tools and explores their complex nature and

Elias Dakwar

PS2023 Harm Reduction Policy and Advocacy Psychedelic Science Public Benefit Research Social Justice

Proactive harm reduction by preparing set, setting, and substance

Harm reduction superheroes delve into risk mitigation and benefit maximization, exploring mindset, setting, and substances for safer drug experiences and systemic change.

Mitchell Gomez, Phoenix aka Mohawk Greene

PS2023 Health Conditions Psilocybin Psychedelic Assisted Therapy Psychedelic Science Research Therapy Ethics

Family Matters in Psychedelic Therapy: Lessons Learned from a Psilocybin Trial for Anorexia Nervosa

Family involvement in psychedelic therapy can optimize outcomes and prevent problematic patterns. Ethical, neurobiological, and psychological aspects, along with clinical trial data, support the benefits of engaging family members.

Jennifer Danby

PS2023 Business Health Conditions Microdosing Psilocybin Psychedelic Science Research

Psilocybin Mushrooms and their Tryptamines: Potential Medicines for Neurogeneration

Paul discusses the historical use and potential for neurological health of psilocybin mushrooms, based on his team's molecular research and clinical studies at MycoMedica Life Sciences.

PS2023 Harm Reduction LSD Policy and Advocacy Psychedelic Science Research Social Justice

Underground History and Overground Future

William Leonard Pickard, once a prominent figure in the drug world, served 20 years in prison for LSD production and now works as a senior advisor for various organizations. His

William Leonard Pickard, Vince Kadlubek

PS2023 Harm Reduction Integration Policy and Advocacy Psychedelic Assisted Therapy Psychedelic Science Research

Responding to Crises and Calls with Psychedelic Harm Reduction

Panelists from Zendo Project, Fireside Project, Kosmicare, and Anashim Tovim discuss harm reduction strategies in the psychedelic ecosystem, emphasizing innovation, compassion, and scientific expertise in diverse settings. They provide case

Joshua White, Daniel E Martin, Pinni Baumol, Shirelle Noble, Ben Halper

PS2023 Harm Reduction Plant Medicine Psychedelic Science Research Research and Science Social and Cultural

The State of the Stone: Science from the Underground

Keynote by psychedelic elders offers historical perspective. Earth and Fire present lab drug checking updates and scientific exploration of psychedelics, risks, benefits, in cultural context.

Fire Erowid, Earth Erowid

PS2023 Harm Reduction Policy and Advocacy Psychedelic Science Public Benefit Research Social Justice

Giving and growth: the role of philanthropic funding in the psychedelic sector

Philanthropy and investors can support crucial psychedelic research and initiatives beyond commercial interests to shape the field and promote equity and social value in the psychedelic economy.

Sandy Samberg

Preliminary results from a Pilot study of the efficacy and safety of ibogaine in the treatment of methadone detoxification

Become a MAPS Member with a monthly donation

Related Videos